Context: The effects of cabergoline on cardiac valves have been extensively studied in Parkinsons disease and hyperprolactinemia but not in acromegaly, a condition at risk of cardiac valve abnormalities.
Objective: We examined the prevalence of heart valve disease and regurgitation in a series of patients with acromegaly treated with cabergoline, by comparison with matched patients who had never received this drug.
Design and setting: Cross-sectional study in a single referral center.
Patients and methods: Forty-two patients who had received cabergoline at a median cumulative dose of 275.6 mg for a median of 34.5 months were compared to 46 patients with acromegaly who had never received cabergoline and who were matched for age, sex and disease duration. Two-dimensional and Doppler echocardiographic findings were reviewed by two cardiologists blinded to treatment.
Results: Demographic and clinical features were not significantly different between the groups. Cabergoline was not associated with a higher prevalence of valve abnormalities. Unexpectedly, a slightly higher prevalence of aortic valve regurgitation and remodeling was found in the controls relative to the cabergoline-treated patients (P<0.02 and P<0.03 respectively) but this was likely related to the presence of an aortic dilation, more prevalent in controls. A prospective study comparing incidence of valve abnormalities in patients with acromegaly treated with cabegoline compared with acromegalics never treated with this drug is ongoing and results will soon be available.
Conclusions: Cabergoline therapy in acromegalic patients is not associated with an increased risk of cardiac valve regurgitation or remodeling.
Declaration of interest: I fully declare a conflict of interest. Details below:
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
05 - 09 May 2012
European Society of Endocrinology